- Tags: dry eye
Pipeline
FDA extends reproxalap's PDUFA to March 2026
Updated target action date applies to Aldeyra’s third NDA submission of the investigational DED eye drop.
Products
Scope's OPTASE HYLO Forte Dry Eye Drops offer long-lasting symptom relief
Clinical experts share OD-MD insights into the advanced artificial tears’ hydrating PF formulation with active glycerin and hyaluronic acid.
Pipeline
Azura gets positive FDA feedback on NDA submission for MGD ointment
Positive pre-NDA meeting for selenium sulfide ointment precedes planned phase 3 data release in Q1 2026 and regulatory submission in H2 2026.
Products
Amneal receives FDA approval for Restasis generic
Generic version of Allergan’s cyclosporine ophthalmic emulsion 0.05% eye drop for dry eye is the second to receive U.S. regulatory clearance.
Research
The Dry Eye Society of the Americas launches as new nonprofit
Founded by leading dry eye specialists, DESA intends to establish dry eye as a recognized subspecialty.
Research
Eyelid irrigating retractor achieves ocular lavage for allergic conjunctivitis
Case study supports use of Rinsada in-office for its additive effect in targeting the beginnings of the allergy cascade to help treat the entire ocular surface.
Research
Phase 3b data supports superior tear response with TRYPTYR
Presented at AAO, new findings stem from measuring tear volume produced following administration of the DED drop.
Products
Topcon launches dry eye imager with robotic intelligence
TERA is a multimodal platform for detecting, grading, and managing DED—and pairs robotic automation with high-res imaging for standardized testing.
Research
New data reinforces XIIDRA's eye dryness relief among CL wearers
Open-label study evaluated effectiveness of lifitegrast 5%, noting significant improvements in end-of-day dryness and discomfort in just 2 weeks.
Products
Scope introduces OPTASE HYLO FORTE dry eye drops
Artificial tear is formulated with active glycerin for moderate-to-severe dry eye disease, offering extra moisture and a protective cushion for long-lasting relief.
Research
TFOS DEWS III report includes use of Lacrifill canalicular gel
Latest installment details two clinical studies validating the use of Nordic Pharma’s FDA-cleared, patented dry eye therapy device.
Research
Cequa's Onset of Action Trial demonstrates rapid ocular surface benefits
Recent data on the FDA-approved, preservative-free eye drop builds on supporting clinical findings—this time for DED patients preparing for refractive-cataract surgery.
Research
24-month data from SAHARA RCT supports TearCare durability for DED
Third set of findings from the long-term study indicates the FDA-cleared system’s ability to deliver “immediate, powerful, repeatable, and long-lasting” dry eye relief.Products
Alcon's TRYPTYR launches to the US market
Company’s first-in-class, prescription-based pharmaceutical features acoltremon, making it the first topical neuromodulator to rapidly increase tear production for DED.
Business
Topcon invests in OKKO Health's home vision monitoring platform
The OKKO Health app is available on patients’ digital devices to enable ongoing self-monitoring of macular degeneration.
Pipeline
FDA accepts Aldeyra's resubmitted reproxalap NDA
Company hopes third submission of the DED application is the charm for achieving marketing approval by a Dec. 26, 2025 PDUFA date.
Research
Bausch + Lomb unveils 2025 state of dry eye survey results
Building on 2024 findings, latest results indicate a need for more patient education to dispel ongoing misconceptions surrounding dry eye.
Pipeline
Stuart Therapeutics reports initial phase 3 DED eye drop data
Results on ST-100 (vezocolmitide), a collagen mimetic peptide, support its role as a fast-acting resolution for dry eye signs and symptoms.
Research
Botox injections may actually help treat DED
Botox injections significantly improved key disease parameters, supporting its potential clinical utility.
Products